These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3196506)

  • 1. Erythropoietin alert: risks of high hematocrit hemodialysis.
    Shinaberger JH; Miller JH; Gardner PW
    ASAIO Trans; 1988; 34(3):179-84. PubMed ID: 3196506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of erythropoietin on the dialysis prescription.
    Van Wyck DB
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):71-5. PubMed ID: 1928083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dialyzer urea and creatinine clearances are not significantly altered in erythropoietin treated maintenance hemodialysis patients.
    Delano BG; Lundin AP; Galonsky R; Quinn-Cefaro RM; Rao TK; Friedman EA
    ASAIO Trans; 1990; 36(1):36-9. PubMed ID: 2306389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of erythropoietin treatment on urea kinetic parameters in hemodialysis patients.
    van Geelen JA; Nubé MJ; Zuurbier PA
    Clin Nephrol; 1991 Apr; 35(4):165-70. PubMed ID: 1855319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between effective ionic dialysance and in vivo urea clearance during hemodialysis.
    Lindsay RM; Bene B; Goux N; Heidenheim AP; Landgren C; Sternby J
    Am J Kidney Dis; 2001 Sep; 38(3):565-74. PubMed ID: 11532690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy.
    Movilli E; Pertica N; Camerini C; Cancarini GC; Brunori G; Scolari F; Maiorca R
    Am J Kidney Dis; 2002 Apr; 39(4):850-3. PubMed ID: 11920353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of hematocrit on solute removal during high efficiency hemodialysis.
    Lim VS; Flanigan MJ; Fangman J
    Kidney Int; 1990 Jun; 37(6):1557-62. PubMed ID: 2362408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary effects of erythropoietin treatment on metabolism and dialysis efficiency in stable hemodialysis patients.
    Buur T; Lundberg M
    Clin Nephrol; 1990 Nov; 34(5):230-5. PubMed ID: 2268981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood and dialysate flow distributions in hollow-fiber hemodialyzers analyzed by computerized helical scanning technique.
    Ronco C; Brendolan A; Crepaldi C; Rodighiero M; Scabardi M
    J Am Soc Nephrol; 2002 Jan; 13 Suppl 1():S53-61. PubMed ID: 11792763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with erythropoietin and loss of dialyser clearance.
    Schaefer RM; Schaefer L
    Nephrol Dial Transplant; 1996; 11 Suppl 2():81-2. PubMed ID: 8804001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dialyzer clearances and mass transfer-area coefficients for small solutes at low dialysate flow rates.
    Leypoldt JK; Kamerath CD; Gilson JF; Friederichs G
    ASAIO J; 2006; 52(4):404-9. PubMed ID: 16883120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease.
    Berns JS; Rudnick MR; Cohen RM; Bower JD; Wood BC
    Kidney Int; 1999 Jul; 56(1):253-60. PubMed ID: 10411700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radionuclide method for evaluating the performance of hemodialysis in vivo.
    Bihl GR; Bird NJ; Peters C; Bradley JR; Peters AM
    Kidney Int; 2005 Feb; 67(2):721-31. PubMed ID: 15673322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are high flux dialysis and erythropoietin treatment in a collision course?
    Acchiardo SR; Quinn BP; Burk LB; Moore LW
    ASAIO Trans; 1989; 35(3):308-10. PubMed ID: 2688711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
    Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of hematocrit on dialyzer urea and creatinine clearance indices in a hemodialysis patient with erythrocytosis.
    Nwosu AC; Tzamaloukas AH; Malhotra D; Saddler MC; Murata GH
    Int J Artif Organs; 1994 Nov; 17(11):591-4. PubMed ID: 7744519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective diffusion volume flow rates (Qe) for urea, creatinine, and inorganic phosphorous (Qeu, Qecr, QeiP) during hemodialysis.
    Gotch FA; Panlilio F; Sergeyeva O; Rosales L; Folden T; Kaysen G; Levin N
    Semin Dial; 2003; 16(6):474-6. PubMed ID: 14629609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rate of increase in hematocrit, humoral vasoactive substances and blood pressure changes in hemodialysis patients treated with recombinant human erythropoietin or blood transfusion.
    Ono K; Hisasue Y
    Clin Nephrol; 1992 Jan; 37(1):23-7. PubMed ID: 1531789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.